Related Experiment Video
Updated: Oct 13, 2025

Point-of-Care Lung Ultrasound in Adults: Image Acquisition
Published on: March 3, 2023
Parapneumonic Effusion and Empyema
Dinesh N Addala1, Eihab O Bedawi1, Najib M Rahman2
1Oxford University Hospitals NHS Foundation Trust; Department of Respiratory Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK.
Abstract:
The rising incidence and high morbidity of pleural infection remain a significant challenge to health care systems worldwide. With distinct microbiology and treatment paradigms from pneumonia, pleural infection is an area in which the evidence base has been rapidly evolving. Progress in recent years has revolved around characterizing the microbiome of pleural infection and the addition of new strategies such as intrapleural enzyme therapy to the established treatment pathway of drainage and antibiotics. The future of improving outcomes lies with personalizing treatment, establishing optimal timing of intrapleural agents and surgery, alongside wider use of risk stratification to guide treatment.
Insights
Pleural infection, a serious lung condition, is increasingly common. New treatments like intrapleural enzymes, combined with personalized medicine and risk assessment, offer improved outcomes for patients.
Area of Science:
- Pulmonology
- Infectious Diseases
- Thoracic Surgery
Background:
- Pleural infection incidence and morbidity pose global health challenges.
- Distinct microbiology and evolving evidence base differentiate it from pneumonia.
- Established treatments include drainage and antibiotics.
Purpose of the Study:
- To review recent advancements in pleural infection management.
- To highlight the role of microbiome characterization and new therapeutic strategies.
- To discuss future directions for optimizing patient outcomes.
Main Methods:
- Literature review of recent studies on pleural infection.
- Analysis of evolving treatment paradigms, including intrapleural enzyme therapy.
- Assessment of microbiome research and risk stratification techniques.
Main Results:
- Characterization of the pleural infection microbiome has advanced.
- Intrapleural enzyme therapy is a new addition to standard care.
- Personalized treatment and risk stratification are emerging strategies.
Conclusions:
- Future improvements depend on personalized treatment approaches.
- Optimizing the timing of intrapleural agents and surgery is crucial.
- Wider use of risk stratification will guide effective patient management.
Related Concept Videos
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Pneumonia II: Pathophysiology
Pleural Effusion I: Introduction
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
Pneumonia III: Complications and Assessment
Pneumothorax-II
Clinical Manifestations:
Pleura of the Lungs

